{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "transcribes",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P18621",
      "entity_text" : "PD-1",
      "entity_type" : "gene"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "cellosaurus:CVCL_0065" ],
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-1006" ],
      "CellType" : [ "cl:CL:0000084" ]
    }
  },
  "verbose_text" : "In cancer immunotherapy, combining antibodies to PD-1 and BTLA might thus also be of therapeutic benefit in conditions in which a tumor mass is heterogeneous in term of PD-1 and BTLA ligand expression.",
  "reading_complete" : "2020-08-08T15:08:12Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T15:02:10Z",
  "trigger" : "expression",
  "evidence" : [ "PD-1 and BTLA ligand expression" ],
  "pmc_id" : "6581740",
  "score" : 0
}